Neuroscience

Managing attention deficit disorder by training the brain

Attention deficit hyperactivity disorder (ADHD) affects about 7% of children, with a two out of three chance of persisting into adulthood. This neurodevelopmental disorder is characterized by concentration difficulties, increased ...

Medications

Trial results of new drug for generalized myasthenia gravis

Argenx, a Belgium pharmaceutical company, recently announced that The Lancet Neurology has published pivotal trial results from the Phase 3 ADAPT trial of efgartigimod, an FcRn antagonist, for the treatment of adults living ...

Biomedical technology

New biochip technology for pharma research

In pharmaceutical research, small tissue spheres are used as mini-organ models for reproducible tests. TU Wien has found a way to develop a reliable standard for these tissue samples.

page 17 from 40